- Home
- AMTB vs FBRX Comparison
AMTB vs FBRX Comparison
Compare AMTB & FBRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | AMTB | FBRX |
|---|---|---|
| Founded | 1979 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 966.6M | 899.4M |
| IPO Year | 2018 | 2017 |
Fundamental Metrics
Financial Performance| Metric | AMTB | FBRX |
|---|---|---|
| Price | $25.77 | $44.36 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 3 |
| Target Price | $23.67 | ★ $67.00 |
| AVG Volume (30 Days) | 314.5K | ★ 824.3K |
| Earning Date | 04-23-2026 | 05-14-2026 |
| Dividend Yield | ★ 1.57% | N/A |
| EPS Growth | ★ 386.36 | 61.30 |
| EPS | ★ 0.44 | N/A |
| Revenue | N/A | ★ $36,000.00 |
| Revenue This Year | $8.29 | N/A |
| Revenue Next Year | $7.67 | N/A |
| P/E Ratio | $58.32 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $15.62 | $9.23 |
| 52 Week High | $26.34 | $45.36 |
Technical Indicators
Market Signals| Indicator | AMTB | FBRX |
|---|---|---|
| Relative Strength Index (RSI) | 62.53 | 83.89 |
| Support Level | $21.68 | $24.72 |
| Resistance Level | $26.34 | N/A |
| Average True Range (ATR) | 0.67 | 3.87 |
| MACD | -0.02 | 2.90 |
| Stochastic Oscillator | 68.73 | 92.19 |
Price Performance
Historical ComparisonAbout AMTB Amerant Bancorp Inc.
Amerant Bancorp Inc is a bank holding company. Through its bank, it provides individuals and businesses deposit, credit, investment, wealth management, and fiduciary services, both in the United States and to select international customers. The bank also provides banking services through traditional channels, such as banking centers and ATMs, as well as via secure websites, mobile devices and telephones.
About FBRX Forte Biosciences Inc.
Forte Biosciences Inc is a clinical-stage biopharmaceutical company that is advancing through preclinical trials its product candidate, FB-102, which is a proprietary anti-CD122 monoclonal antibody therapeutic candidate with potentially broad autoimmune and autoimmune-related indications. The Company is also advancing clinical development of FB102 in patient-based trials for non-segmental vitiligo and alopecia areata.